MNPR 📈 Monopar Therapeutics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US61023L1089
MNPR: Cancer, Imaging, Radiotherapy, Chemotherapy
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC. Web URL: https://www.monopartx.com
Additional Sources for MNPR Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MNPR Stock Overview
| Market Cap in USD | 141m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2019-12-19 |
MNPR Stock Ratings
| Growth 5y | -59.9% |
| Fundamental | -33.0% |
| Dividend | - |
| Rel. Strength Industry | - |
| Analysts | 4.67/5 |
| Fair Price Momentum | 21.58 USD |
| Fair Price DCF | - |
MNPR Dividends
No Dividends PaidMNPR Growth Ratios
| Growth Correlation 3m | 90% |
| Growth Correlation 12m | 69% |
| Growth Correlation 5y | -85.5% |
| CAGR 5y | -24.31% |
| CAGR/Mean DD 5y | -0.29 |
| Sharpe Ratio 12m | 1.26 |
| Alpha | 980.34 |
| Beta | 0.64 |
| Volatility | 159.04% |
| Current Volume | 20k |
| Average Volume 20d | 93.1k |
What is the price of MNPR stocks?
As of January 01, 2025, the stock is trading at USD 22.00 with a total of 19,996 shares traded.
Over the past week, the price has changed by -0.23%, over one month by -0.05%, over three months by +226.41% and over the past year by +1089.19%.
As of January 01, 2025, the stock is trading at USD 22.00 with a total of 19,996 shares traded.
Over the past week, the price has changed by -0.23%, over one month by -0.05%, over three months by +226.41% and over the past year by +1089.19%.
Is Monopar Therapeutics a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Monopar Therapeutics (NASDAQ:MNPR) is currently (January 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -33.00 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MNPR as of January 2025 is 21.58. This means that MNPR is currently overvalued and has a potential downside of -1.91%.
Probably not. Based on ValueRay Fundamental Analyses, Monopar Therapeutics (NASDAQ:MNPR) is currently (January 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -33.00 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MNPR as of January 2025 is 21.58. This means that MNPR is currently overvalued and has a potential downside of -1.91%.
Is MNPR a buy, sell or hold?
Monopar Therapeutics has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy MNPR.
Monopar Therapeutics has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy MNPR.
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for MNPR stock price target?
According to ValueRays Forecast Model, MNPR Monopar Therapeutics will be worth about 23.3 in January 2026. The stock is currently trading at 22.00. This means that the stock has a potential upside of +5.95%.
According to ValueRays Forecast Model, MNPR Monopar Therapeutics will be worth about 23.3 in January 2026. The stock is currently trading at 22.00. This means that the stock has a potential upside of +5.95%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 27.3 | 24.2% |
| Analysts Target Price | 8.5 | -61.4% |
| ValueRay Target Price | 23.3 | 6% |